Relugolix combination therapy vs relugolix monotherapy with transition to relugolix combination therapy for the treatment of endometriosis-associated pain: implications for cumulative benefit/risk profile

被引:0
作者
Becker, C. [1 ]
As-Sanie, S. [2 ]
Zhai, D. [3 ]
Perry, J. S. [4 ]
Dynowski, K. [5 ]
Wilk, K. [6 ]
Wagman, R. B. [4 ]
Rakov, V. G. [7 ]
McClung, M. R. [8 ]
机构
[1] Univ Oxford, Nuffield Dept Womens & Reprod Hlth, Headington Oxford, England
[2] Univ Michigan, Obstet & Gynecol, Ann Arbor, MI USA
[3] Sumitomo Pharma Amer Inc, Biostat, Cambridge, MA USA
[4] Sumitomo Pharma Amer Inc, Clin Dev, Cambridge, MA USA
[5] Med Ctr Postgrad Educ, Clin Res, Warsaw, Poland
[6] Boni Fratres Hosp, Obstet & Gynecol, Katowice, Poland
[7] Sumitomo Pharma Switzerland GmbH, Med Affairs, Basel, Switzerland
[8] Oregon Osteoporosis Ctr, Portland, OR USA
关键词
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
P-308
引用
收藏
页数:2
相关论文
empty
未找到相关数据